Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Mental Health Clinical Trials Market Revenue Growth Supported By A CAGR Of 4.88% Through 2030
The mental health clinical trials market has experienced significant growth over recent years. This market is projected to expand from $3.23 billion in 2025 to $3.52 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.9%. Historically, this expansion has been driven by factors such as the rising incidence of mental health disorders, the broadening of pharmaceutical research pipelines, enhanced public awareness of mental health conditions, increased funding for clinical research, and a greater adoption of standardized diagnostic criteria.
The mental health clinical trials market size is projected to experience substantial expansion in the coming years. This sector is anticipated to reach $4.89 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.6%. The anticipated growth during this period stems from factors such as the increasing embrace of digital mental health interventions, heightened investments in personalized psychiatry research, the broadening of global mental health trial networks, increasing regulatory encouragement for novel trial designs, and greater utilization of data-driven outcome assessments. Key developments expected within the forecast timeframe encompass the wider acceptance of decentralized clinical trial models, a surge in the application of digital therapeutics in trials, the growing incorporation of AI-based tools for patient recruitment, the expansion of remote patient monitoring in studies, and a sharpened emphasis on generating real-world evidence.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27343&type=smp
Mental Health Clinical Trials Market Growth Factors: Which Forces Are Supporting Market Expansion?
The increasing occurrence of mental health conditions is anticipated to drive the expansion of the mental health clinical trials market moving ahead. These disorders are defined as states that markedly impact an individual’s feelings, cognition, actions, and general psychological well-being. The escalation in mental health disorders stems from heightened stress levels associated with contemporary lifestyles, encompassing professional demands, limited social interaction, and continuous digital engagement. Clinical trials in mental health play a crucial role in advancing treatment by assessing the security and efficacy of novel medications, treatments, and behavioral strategies for mental health conditions. As an illustration, in May 2024, the American Psychiatric Association, a US-based non-profit body, indicated that approximately 43% of adults in the USA reported feeling more anxious in 2024, representing an increase from 37% in 2023 and 32% in 2022. Consequently, the growing occurrence of mental health disorders is fueling the expansion of the mental health clinical trials market.
Mental Health Clinical Trials Market Segment Analysis: What Are The Major Market Categories?
The mental health clinical trials market covered in this report is segmented –
1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Study Design: Interventional, Observational, Other Study Designs
3) By Disorder: Anxiety Disorders, Depression, Bipolar Affective Disorder, Dissociation And Dissociative Disorders, Schizophrenia, Other Disorders
4) By Sponsor: Pharmaceutical And Biopharmaceutical Companies, Government Agencies, Other Sponsors
Subsegments:
1) By Phase I: Single Ascending Dose, Multiple Ascending Dose, First In Human, Pharmacokinetics Studies
2) By Phase II: Dose Ranging Studies, Proof Of Concept Studies, Randomized Controlled Trials, Open Label Studies
3) By Phase III: Large Scale Randomized Trials, Multicenter Studies, Comparative Effectiveness Trials, Double Blind Studies
4) By Phase IV: Post Marketing Surveillance, Long Term Safety Studies, Real World Evidence Studies, Pharmacovigilance Studies
Mental Health Clinical Trials Market Industry Trends: What Changes Are Reshaping Demand?
Companies operating within the mental-health clinical trials market are increasingly concentrating on developing innovative solutions, such as software-enhanced drug therapies, to improve treatment efficacy, personalize patient care, and enhance real-world therapeutic outcomes. These software-enhanced drug therapies involve combining traditional medications with clinically validated therapeutic software to help improve patient outcomes by personalizing care, boosting adherence, and offering real-time behavioral or symptom-management support. As an illustration, in October 2024, Click Therapeutics Inc., a US-based digital therapeutics company, introduced Click SE, a new offering designed to pioneer software-enhanced drug therapies that integrate prescription software with pharmacotherapy to provide additional clinical benefit and facilitate novel endpoints in mental-health clinical development. Click SE is a software-centric product family, made up of regulated mobile and cloud applications built on Click’s AI-enabled DTx platform. It operates by delivering structured therapeutic programs, real-time symptom monitoring, and medication-specific digital support intended to synergize with a co-prescribed drug. Notable features include adaptive algorithms that tailor content to patient response, integration pathways for pharmacologic dosing schedules, and built-in metrics for objective trial endpoints; its applications encompass augmenting antipsychotics for negative symptoms, serving as an adjunctive therapy in depression, and providing support in substance-use disorders.
Mental Health Clinical Trials Market Leading Companies Driving Competitive Growth
Major companies operating in the mental health clinical trials market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials, Inc., Ergomed, Celerion Inc., Biotrial S.A.S., Lindus Health Ltd., Novotech Health Holdings Pte Ltd., Precision for Medicine Inc.
Access The Complete Mental Health Clinical Trials Market Report:
https://www.thebusinessresearchcompany.com/report/mental-health-clinical-trials-global-market-report
Mental Health Clinical Trials Market Largest Region By Revenue And Market Share
North Americawas the largest region in the mental health clinical trials market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the mental health clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
